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Abstract A tissue microarray (TMA) has previously been
developed for use in assessment of neurodegenerative dis-
eases. We investigated the variation of pathology loads in
semi-quantitative score categories and how pathology load
related to disease progression. Post-mortem tissue from 146
cases were used; Alzheimer’s disease (AD) (n = 36), Lewy
body disease (LBD) (n = 56), mixed AD/dementia with
Lewy bodies (n = 14) and controls (n = 40). TMA blocks
(one per case) were constructed using tissue cores from 15
brain regions including cortical and subcortical regions.
TMA tissue sections were stained for hyperphosphorylated
tau (HP-T), b amyloid and a-synuclein (asyn), and quanti-
fied using an automated image analysis system. Cases
classified as Braak stage VI displayed a wide variation in
HP-T pathology in the entorhinal cortex (interquartile range
4.13–44.03%). The interquartile range for b amyloid in
frontal cortex in cases classified as Thal phase 5 was
6.75–17.03% and for asyn in the cingulate in cases classified
as McKeith neocortical LBD was 0.04–0.58%. In AD and
control cases, HP-T load predicted the Braak stage
(p\ 0.001), b amyloid load predicted Thal phase
(p\ 0.001) and asyn load in LBD cases predicted McKeith
type of LBD (p\ 0.001). Quantitative data from TMA
assessment highlight the range in pathological load across
cases classified with ‘severe’ pathology and is beneficial to
further elucidate the heterogeneity of neurodegenerative
diseases. Quantifying pathology in multiple brain regions
may allow identification of novel clinico-pathological phe-
notypes for the improvement of intra vitam stratification of
clinical cohorts according to underlying pathologies.
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Introduction
Clinico-pathological correlative studies in dementia
research have provided significant contributions into
understanding how pathological protein aggregations in the
brain correspond to the clinical manifestation of dementia.
Seminal studies have demonstrated features of senile pla-
que accumulation and neurofibrillary tangle formation are
essential to the neuropathological diagnosis of Alzheimer’s
disease (AD) (Tomlinson et al. 1970) and more specifically
emphasizing the importance of dystrophic neurites positive
for hyperphosphorylated tau in neuritic plaques in AD
cases compared to controls (Dickson et al. 1988; Probst
et al. 1989; Arai et al. 1990). However, as patients were
historically dichotomized as AD or normally aged controls,
these studies lacked detail required to track disease pro-
gression. Later studies utilized semi-quantitative staging
systems (based on 4 and 5-tiered staging scales) for diag-
nostics, and correlated pathological load against clinical
measures of cognitive impairment (Braak and Braak 1991;
Mirra et al. 1991; McKeith et al. 1996; Braak et al. 2003),
giving further insight into the relative contribution of each
pathology to clinical phenotype.
Neurodegenerative diseases by nature can be heteroge-
neous, and not all can be classified using current diagnostic
On the occasion of Professor Kurt Jellinger’s 85th birthday for his
continuous support, inspiration and friendship!
& Lauren Walker
lauren.walker1@ncl.ac.uk
& Johannes Attems
j.attems@ncl.ac.uk
1 Institute of Neuroscience, Newcastle University, Campus for
Ageing and Vitality, Newcastle upon Tyne NE4 5PL, UK
123
J Neural Transm (2017) 124:671–683
DOI 10.1007/s00702-017-1702-2
criteria (Beach et al. 2009; Nelson et al. 2010), with semi-
quantitative grades masking subtle differences in patho-
logical burden. However, the recent advances in quantita-
tive automated image analysis technologies have enabled
the assessment of large scale cohorts and offers accurate
and reproducible methods that can be implemented by
researchers with varying degrees of neuropathology expe-
rience (Neltner et al. 2012; Attems et al. 2014). Using such
technologies, differences in cases that classify as having
‘severe’ pathology have been reported; Murray and col-
leagues identified three distinct clinico-pathological phe-
notypes of AD (all Braak stage[ IV), which have
subsequently been predicted intra vitam by MRI (Whitwell
et al. 2012), demonstrating direct translational impact of
quantitative neuropathological data. In cases fulfilling
neuropathological criteria for mixed dementia [AD and
limbic/neocortical (LBD)] with different clinical pheno-
types (i.e., AD or DLB), we found differences in the
pathological burden and topographical distribution of
hyperphosphorylated tau (HP-T), b amyloid and a-synu-
clein (a-syn) loads between clinical AD and DLB which
were not detected using semi-quantitative criteria (Walker
et al. 2015).
Clinico-pathological studies and in particular those that
use quantitative methodologies are very labor intensive,
which may limit the number of cases included in cohorts.
As such, current studies are either: (1) very comprehensive,
in which numerous brain regions are included but have
relatively small sample sizes (Arriagada et al. 1992;
Molano et al. 2010), (2) have a reasonable cohort size but
include fewer brain regions included in the study (McKee
et al. 1991; Kazee et al. 1993; Bartoo et al. 1997; Kovari
et al. 2003), or (3) include large cohort sizes but pathology
is assessed using neuropathological staging criteria or
semi-quantitative scales which are not as time consuming
(Jellinger 2006; Kovari et al. 2014). To address these
limitations and to tease out discreet clinico-pathological
phenotypes, it seems necessary for future studies to have
large cohorts with numerous brain regions quantitatively
assessed for multiple pathological lesions.
Tissue microarray (TMA) is a technique most com-
monly employed in tumor studies, which allows a large
number of samples from individual cases to be relocated
into a single block suitable for high throughput analysis
(Kononen et al. 1998; Bubendorf et al. 2001), and has
previously been employed to investigate white matter dis-
ease in a small sample of AD cases, highlighting its
potential use in dementia research (Sjobeck et al. 2003).
Here, we describe the application of TMA methodology to
assess 15 anatomically distinct brain regions (40 samples in
total) from any given case. In addition, we report on initial
results from 146 cases (AD, LBD, mixed AD/LBD and
controls) that have undergone TMA analysis for common
neurodegenerative pathologies and illustrate a huge varia-
tion in pathology burden, in particular those classified as
having ‘severe’ pathology by current diagnostic criteria
(Thal et al. 2002; McKeith et al. 2005; Braak et al. 2006;
Alafuzoff et al. 2008).
Materials and methods
Tissue preparation and neuropathological diagnosis
Brain tissue from 146 donors (mean age 79.91, SE
±0.72 years; male 89; female 57; AD 36; LBD (inclusive
of DLB, PDD and PD) 56; mixed AD/DLB 14 and non-
demented controls 40 (Table 1)], was obtained from
Newcastle Brain Tissue Resource (NBTR) as part of a
consecutive case series in accordance with the approval of
the joint Ethics Committee of Newcastle and North
Tyneside Health Authority and following NBTR brain
banking procedures. During life, patients underwent clini-
cal assessments including Mini-mental state examination
(MMSE) (Folstein et al. 1975) by board certified Old Age
Psychiatrists or Neurologists and clinical diagnoses were
reviewed by AJT and IGM post-mortem, blinded to neu-
ropathological diagnosis and checked against relevant
standard international clinical criteria (McKhann et al.
1984, 2011; McKeith et al. 2005; Emre et al. 2007).
At autopsy the right hemisphere, brainstem and cerebellum
were immersion fixed in 4% buffered aqueous formaldehyde
for 4–6 weeks. Following fixation, the right hemisphere was
dissected in coronal planes approximately 0.7 cm intervals
and subjected to standard macroscopic examination, and brain
regions required to determine the neuropathological diagnosis
were sub-dissected and processed through increasing con-
centrations of alcohol then chloroform to paraffin wax. Sub-
sequently, all brains underwent standard neuropathological
assessment using internationally accepted criteria including
neuritic Braak stages (Alafuzoff et al. 2008), Thal amyloid
phases (Thal et al. 2002), CERAD scores (Mirra et al. 1991),
NIA-AA scores (Montine et al. 2012) and McKeith criteria
(McKeith et al. 2005).
TMA construction
Each case was then sampled to compose a TMA block.
Areas that were sampled for the TMA were taken from
paraffin embedded (donor) blocks containing: pre-frontal
cortex [Brodmann area 9 (BA), 10/46], mid-frontal cortex,
(BA8, 9), cingulate gyrus (BA24, 32), caudate, putamen,
external globus pallidus, amygdala, insular cortex, motor
cortex (BA4), thalamus, entorhinal cortex, temporal cortex
(BA21, 22, 41/42), parietal cortex (BA22, 40) and occipital
cortex (BA17, 18, 19, 19/37) (Fig. 1).
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Fixed paraffin donor blocks were warmed for 1 h at
37 C to aid tissue removal. 3 mm cylindrical tissue cores
were taken from predefined positions using a hand held
tissue sampler (Tissue-Tek Quick-RayTM TMA system,
Sakura, CA, USA). The tip of the hand held punch was
inserted at the correct position through the depth of the
tissue in the donor block and removed along with the
cylindrical tissue core (Fig. 2a). Each tissue core was then
inserted into the correct ‘hole’ in a single, regular sized
pre-made recipient TMA paraffin block (4 cm 9 3 cm—
made to perfectly match the Tissue-Tek Quick-RayTM
TMA system) in numerical order (Fig. 2b). If any donor
blocks are missing, empty ‘holes’ in recipient block were
filled with molten wax. Each of the punches was pushed
securely into the recipient block by hand and the block
incubated at 37 C to reduce the wax–tissue interface when
sectioning.
An in-house silicone mould, made specifically to fit the
TMA recipient block, was preheated to 60 C for 1 h and
2–4 ml of molten paraffin wax placed into the base. The
recipient TMA block was placed tissue face down onto the
molten wax and left for 5 min before a further 15 min
incubation at 37 C to anneal (Fig. 2c). The block was
allowed to cool fully before the silicone mould was
removed and excess wax removed. TMA sections were
then cut and mounted onto glass slides (Fig. 2d) and
immunohistochemically stained for HP-T (AT8 clone,
Innogenetics, Belgium), b amyloid (4G8 clone, Covance,
UK) and a-syn (Leica, UK) as described previously
(Walker et al. 2015).
Image analysis
TMA slides were analyzed using an automated system
consisting of a Nikon Eclipse 90i microscope, DsFi1
camera and NIS Elements software v 3.0 (Nikon). Sec-
tions were placed onto the microscope in the correct ori-
entation to position tissue core 1 in the top left field of
view. To capture images of each of the 40 tissue cores on
the TMA slide, the microscope was positioned in the center
of the first tissue core at 209 magnification for guidance
and brought into focus at 1009 magnification. The co-
ordinates of this first tissue core were then mapped using a
macro designed to take large images comprised of 3 9 3
small images measuring 1.7 mm2. The microscope was
then positioned over the center of the second tissue core
and the process repeated until the positions of all 40 tissue
cores had been mapped. If any of the tissue cores were
Table 1 Patient demographics
AD LBD Mixed AD/DLB Control
Case (n) 36 56 14 40
Age at death (mean, ± SE) 83.17 (1.32) 78.1 77.57 (1.50) 80.30 (1.86)
% Female 50 25 28.6 52.5
Braak NFT stage (Braak et al. 2006) Stage 4 n = 1
Stage 5 n = 4
Stage 6 n = 31
Stage 0 n = 2
Stage 1 n = 7
Stage n = 14
Stage 3 n = 24
Stage 4 n = 9
Stage 5 n = 4
Stage 6 n = 10
Stage 0 n = 6
Stage 1 n = 8
Stage 2 n = 15
Stage 3 n = 9
Stage 4 n = 2
Thal phase (Thal et al. 2002) Phase 4 n = 4
Phase 5 n = 32
Phase 0 n = 6
Phase 1 n = 3
Phase 2 n = 1
Phase 3 n = 6
Phase 4 n = 6
Phase 5 n = 4
NA n = 30
Phase 4 n = 1
Phase 5 n = 13
Phase 0 n = 13
Phase 1 n = 10
Phase 2 n = 6
Phase 3 n = 5
Phase 4 n = 1
Phase 5 n = 3
NA n = 2
CERAD (Mirra et al. 1991) B n = 1
C n = 35
Negative n = 31
A n = 14
B n = 11
C n = 14 Negative n = 35
A n = 2
B n = 3
McKeith criteria (McKeith et al. 2005) Negative n = 36 Limbic n = 13
Neocortical n = 43
Limbic n = 1
Neocortical n = 13
Negative n = 38
Brainstem n = 1
Amygdala predominant n = 1
MMSE (Folstein et al. 1975) 8.45 (1.81) 15.85 (1.82) 12.38 (3.34) 25.84 (1.53)
AD Alzheimer’s disease, LBD Lewy body disease, n number, NFT neurofibrillary tangle, NA not available, CERAD consortium to establish a
registry for Alzheimer’s disease, MMSE mini-mental state examination
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missing or too damaged to be included in the analysis the
tissue core number was noted and this was factored into the
analysis. Once all 40 tissue cores were mapped, the
microscope was directed to the co-ordinates of the first
tissue core and the images of all tissue cores were auto-
matically taken in sequence. Regions of interest (ROI)
were applied to individual images if necessary to exclude
any white matter or abnormalities in the tissue (e.g., folded
tissue or tears). Restriction threshold was applied to capture
all immunopositive signals. The measurement of
immunopositivity and subsequent calculation of the per-
centage area covered by immunopositivity was performed
using an automated methodology. Red, Green and Blue
(RGB) thresholds that determine the pixels that are inclu-
ded in the binary layer used for measurement were stan-
dardized separately for each AT8, 4G8 and a-syn
immunopositivity and thresholds were set at a level that
was reached by immunopositive pathological structures
Fig. 1 Diagram illustrating the locations where each of the tissue
micro array (TMA) tissue cores were extracted from each diagnostic
tissue block. Tissue cores 1–4 were taken from the pre-frontal cortex,
5–8 from mid-frontal cortex, 9 and 10 from the cingulate cortex,
caudate, putamen, external globus pallidus, amygdala and insular
cortex (11–16 ? 19), 17 and 18 from motor cortex, thalamus (20),
21–25 from entorhinal cortex, 26–30 from temporal cortex, 31–35
from parietal cortex and 36–40 from occipital cortex. White circles
and black numbers represent the tissue cores with numeric label. Gray
numbers and color coding represent Brodmann areas Adapted from
(Perry and Oakley 1993)
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only (except APP; see below). RGB intensity values are
measured on a scale between 0 and 255 (see NIS elements
version 3.0, user guide, 2008, Nikon, Surrey UK) and were
set as follows; AT8: R25–170, G27–156, B11–126; 4G8:
R50–180, G20–168, B8–139, a-syn: R15–161, G7–139,
B4–133 (Fig. 3). Thereby, unspecific background staining
did not reach the threshold and was not included into the
measurement. In addition to RGB thresholds, we set a
restriction threshold for the assessment of 4G8
immunopositivity that excluded the measurement of
immunopositive signals of a size below 100 lm2; this was
necessary to ensure that physiological, cellular APP that is
stained with 4G8 antibody was not included in the mea-
surement. Of note, the exclusion of areas below 100 lm2
implies that pathological b amyloid depositions of less than
100 lm2 were not included into the measurement. How-
ever, diffuse b amyloid depositions and b amyloid plaques
are typically larger than 100 lm2 (Duyckaerts et al. 2009).
Of note, only immunoreactive neurones harboring HP-T
positive NFTs and NTs were quantified in sections stained
with AT8 antibody. Glial HP-T pathology such as for
example seen in progressive supranuclear palsy (Dickson
et al. 2007), corticobasal degeneration (Dickson et al.
2002), and aging-related tau-astrogliopathy (ARTAG)
(Kovacs et al. 2016) was identified on visual inspection and
excluded when quantifying pathology as part of TMA. In
addition, TMA punches that were devoid of b amyloid
plaques but had severe cerebral amyloid angiopathy on
4G8 stained sections were disregarded in quantitative
analysis. Percentage area of the tissue covered by
immunopositivity was subsequently calculated and for
brain regions that had more than one tissue core, mean
values were calculated.
Statistical analysis
Statistical analysis was conducted using the Statistical
Package for Social Sciences (SPSS v 22, IBM). Data was
tested for normality using Kolmogorov–Smirnov test fol-
lowed by visual inspection of variable histograms. Krus-
kal–Wallis was used to determine overall differences
between groups and a non-parametric t test (Mann–Whit-
ney U) to assess post hoc differences between individual
groups. Spearman’s correlation coefficients (two tailed)
were used to assess associations between pathology load
with pathological stages and MMSE scores. Exploratory
linear regression analyses were conducted to investigate
predictors of disease progression and cognitive decline.
Fig. 2 Schematic illustrating the production of the Tissue Microarray
(TMA) block. 3 mm cylindrical tissue cores are taken from pre-
defined positions from fixed paraffin embedded donor blocks using a
hand held tissue sampler (a). Each core is then inserted into the
correct hole in a pre-made recipient block in numerical order (b). The
completed recipient block is then placed face down in a mould
specifically made to fit the block with 2–4 ml of molten wax in the
bottom, and left to anneal (c). TMA sections are then cut at 6 lm and
mounted onto glass slides (d)
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Results
Neocortical pathology increases with disease
progression
Mean neocortical HP-T load increased significantly
(p\ 0.001) with increasing NFT Braak stage in all neo-
cortical regions (Fig. 4a), as did neocortical b amyloid
(p\ 0.001) in line with increasing Thal phases (Fig. 4b).
Although a-syn load was higher in all regions classified as
neocortical LBD compared to limbic LBD, only the
increase in temporal lobe a-syn load was significant
(p\ 0.05) (Fig. 4c). For post hoc statistics see Table 2.
Variation of pathology in ‘severe’ semi-quantitative
grades
Of the cases classified as Braak stage VI, the median HP-T
load in the entorhinal cortex was 20.96%; however, the
range of HP-T load was extensive (minimum 0.43%,
maximum 71.48% and interquartile range 4.13–44.03%)
(Fig. 5a). In cases classified as Thal phase 5 the median b
amyloid load in the frontal cortex was 11.45% (minimum
1.03%, maximum 51.03% and interquartile range
6.75–17.03%) (Fig. 5b). Cases that fulfilled McKeith cri-
teria for neocortical LBD harbored a median a-syn load of
0.2% (minimum 0.001%, maximum 1.85%, interquartile
range 0.04–0.58%) in the cingulate cortex (Fig. 5c).
Associations between pathology load with staging
criteria and cognitive decline
We investigated whether HP-T load in the entorhinal cortex
was associated with disease progression as measured by
NFT Braak stage and cognitive decline as measured by
MMSE. AD and control cases were selected to display a
full range of NFT Braak stages. HP-T load positively cor-
related with NFT Braak stage (rs = 0.714, p\ 0.01)
(Fig. 6a). In cases where MMSE scores were available
(n = 37), HP-T load negatively correlated with MMSE
score (rs = -0.420, p\ 0.01) (Fig. 6b). In AD and control
cases b amyloid load in the frontal cortex positively cor-
related with Thal phase (rs = 0.818, p\ 0.01) (Fig. 6c)
and frontal b amyloid load negatively correlated with
Fig. 3 Photomicrographs illustrating immunohistochemically stained
pathology (a–c) and the application of a standardized threshold
designed to capture all immunopositive signals to be included in the
quantitative analysis (red outline in ai–ci). Neurofibrillary tangles
(black arrow) and neuropil threads (black arrowhead) are
immunopositive for HP-T (AT8 antibody) (a) and with threshold
applied—red outline (ai). Plaques are immunopositive for b amyloid
(4G8 antibody) (b) and with the threshold applied—red outline (bi).
Intracellular amyloid precursor protein is also immunopositive using
4G8 antibody and is excluded from the quantitative analysis using a
size restriction threshold (red arrows) (bi). Lewy bodies (green
arrows) and Lewy neurites (green arrowheads) are immunopositive
for a-syn (a-syn antibody) (c) and with threshold applied—red
outline (ci). Scale bar in a represents 50 lm and is valid for all
images
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MMSE score (rs = 0.676, p\ 0.01) (Fig. 6d). Whilst in
LBD and control cases, a-syn load in the cingulate posi-
tively correlated with disease progression as measured by
McKeith criteria (rs = 0.875, p\ 0.01) (Fig. 6e). In cases
where MMSE scores were available (n = 39) a-syn load in
the cingulate negatively correlated with MMSE score
(rs = 0.690, p\ 0.01) (Fig. 6f).
Pathology load predicts disease progression
and cognitive decline
To address whether pathology load could predict disease
progression and cognitive decline as measured by MMSE, we
performed exploratory linear regression analyses in AD, LBD
and control cases. HP-T load in the entorhinal cortex predicted
both NFT Braak stage (model R2 = 0.324, F(1) = 35.423,
p\ 0.001) and MMSE score (model R2 = 0.116,
F(1) = 4.873, p\ 0.05). In AD and control cases, b amyloid
load in the frontal cortex predicted Thal phase (model
R2 = 0.421, F(1) = 48.025, p\ 0.001) and MMSE score
(model R2 = 0.413, F(1) = 25.277, p\ 0.001). Whilst in
LBD and control cases a-syn load in the cingulate predicted
disease progression as classified by McKeith criteria (model
R2 = 0.260, F(1) = 43.959, p\ 0.001) and MMSE score
(model R2 = 0.119, F(1) = 4.983, p\0.05).
Discussion
Using a TMA-based methodology, we have developed an
automated quantification technique capable of accurately
assessing multiple pathological lesions in a range of
Fig. 4 Mean neocortical hyperphosphorylated tau (HP-T), b amyloid and a-synuclein (a-syn) load significantly increases in line with
neurofibrillary tangle (NFT) Braak stages, Thal phases and McKeith criteria. For mean values and statistics, see Table 2
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neurodegenerative diseases, whilst the inclusion of 15 brain
regions, represented by a total of 40 samples, provides a
platform to study post-mortem tissue on a systems level in
the neuropathology context. Data from 146 cases currently
analyzed displayed a wide variation in pathology load in
semi-quantitative grades in particular HP-T load in cases
classified as NFT Braak VI. This is in agreement with a
previous study by Abner and colleagues, who observed an
appreciable range in neurofibrillary pathology in neocorti-
cal regions in Braak stage VI cases, with the most severely
affected cases displaying increased ante-mortem cognitive
impairment (Abner et al. 2011). Such variations in
pathology highlights the need for quantitative neu-
ropathological assessment in future clinico-pathological
studies, as Braak staging can mask severe variations in
pathology severity and may account for some of the
heterogeneity observed in neurodegenerative diseases in
addition to hindering identification of discreet novel clin-
ico-pathological phenotypes. Although the TMA method-
ology presented here allows the accurate assessment of
pathological lesions in multiple brain regions, there is an
inherent bias associated with this type of technique. It has
been previously shown that densities of pathological pro-
tein aggregates (e.g., b amyloid) differs between gyri and
sulci (Gentleman et al. 1992), and as such we have tried to
limit anatomical bias by sampling gyri and sulci of each
cortical region within the TMA block. Other brain regions
incorporated into the TMA block, such as the striatum and
Table 2 Neocortical pathology
burden of hyperphosphorylated
tau, b amyloid, and a-synuclein
and neuropathological criteria
Braak NFT stage
I/II (n = 47) III/IV (n = 42) V/VI (n = 57) Statistic*
HP-T load
Frontal % (± SE) 0.07 (0.01) 0.10 (0.02) 12.29 (2.48) p\ 0.001a
Temporal % (± SE) 0.26 (0.14) 0.60 (0.33) 20.58 (2.85) p\ 0.001b
Parietal % (± SE) 0.06 (0.02) 0.70 (0.52) 18.07 (2.90) p\ 0.001c
Occipital % (± SE) 0.04 (0.01) 0.37 (0.17) 15.04 (2.56) p\ 0.001d
Thal Ab phase
1 (n = 13) 2 (n = 7) 3 (n = 11) 4 (n = 5) 5 (n = 45) Statistic*
Ab load
Frontal % (± SE) 0.13 (0.07) 3.80 (1.80) 2.91 (0.69) 8.29 (1.20) 12.80 (1.44) p\ 0.001e
Temporal % (± SE) 0.26 (0.20) 1.94 (1.07) 3.00 (0.82) 5.97 (1.42) 10.76 (1.04) p\ 0.001f
Parietal % (± SE) 0.09 (0.44) 2.82 (1.73) 2.82 (0.91) 7.37 (1.87) 10.63 (1.08) p\ 0.001g
Occipital % (± SE) 0.17 (0.09) 1.55 (0.79) 2.27 (0.73) 4.86 (1.07) 7.02 (5.99) p\ 0.001h
McKeith criteria
Limbic (n = 7) Neocortical (n = 36) Statistic**
a-Syn load
Frontal % (± SE) 0.06 (0.04) 0.20 (0.07) ns
Temporal % (± SE) 0.04 (0.02) 0.17 (0.04) p\ 0.05
Parietal % (± SE) 0.05 (0.04) 0.16 (0.06) ns
Occipital % (± SE) 0.02 (0.01) 0.09 (0.03) ns
NFT neurofibrillary tangle, n number, HP-T hyperphosphorylated tau, SE standard error, Ab amyloid beta,
a-syn alpha-synuclein, ns not significant
* Kruskal–Wallis test, Pairwise post hoc Mann–Whitney U tests
** Mann Whitney U test
a I/II\ III/IV (p\ 0.01), I/II\V/VI and III/IV\V/VI (both p\ 0.001)
b I/II\ III/IV (p\ 0.01), I/II\V/VI and III/IV\V/VI (both p\ 0.001)
c I/II\ III/IV (p\ 0.01), I/II\V/VI and III/IV\V/VI (both p\ 0.001)
d I/II\ III/IV (p\ 0.01), I/II\V/VI and III/IV\V/VI (both p\ 0.001)
e 1\ 3, 1\ 4, 1\ 5, 3\ 5 (all p\ 0.001) and 2\ 5, 3\ 4 (p\ 0.01)
f 1\ 3, 1\ 4, 1\ 5, 2\ 5 3\ 5 (all p\ 0.001) and 4\ 5 (p\ 0.05)
g 1\ 3, 1\ 4, 1\ 5, 3\ 5 (all p\ 0.001) and 2\ 3 (p\ 0.01)
h 1\ 3, 1\ 4, 1\ 5 (all p\ 0.001), 3\ 5 (p\ 0.01) and 2\ 4 (p\ 0.05)
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thalamus, are more complex structures containing multiple
nuclei, and whilst this technique is aimed at providing an
overview of pathology present, we suggest a more com-
prehensive sampling protocol when investigating individ-
ual brain regions.
Previous studies have demonstrated that staging disease
progression using standardized criteria is the most accurate
correlate of the neurodegenerative process (Braak and
Braak 1991; Bancher et al. 1996), however, here, we have
demonstrated that HP-T, b amyloid and a-syn load in
individual brain regions increases with, and is a predictor
of increasing neuropathological stage. In addition we have
shown that HP-T, b amyloid and a-syn loads in the
entorhinal cortex, frontal cortex and cingulate cortex,
respectively, are predictors of cognitive decline as mea-
sured by MMSE, which highlights the importance of
multiple pathologies in neurodegeneration and this may
have implications for future therapeutic design strategies.
A recent study by Koss and colleagues found pre-fibrillar
soluble forms of HP-T and b amyloid are present early in
the disease course and are closely linked to disease pro-
gression and cognitive impairment (Koss et al. 2016).
Therefore, targeting pre-fibrillar forms of HP-T and b
amyloid or insoluble deposits in the early stage of disease
before considerable accumulation may be a more effective
treatment strategy. However, research into prion-like
mechanisms involved in propagation of misfolded proteins
in neurodegenerative diseases is gathering pace, with drug
development targeted at halting the cell to cell transmission
of toxic protein aggregates (for reviews see Frost and Dia-
mond 2010; Hasegawa et al. 2016). It is, therefore, essential
to address both the accumulation of pathological aggregations
in a given region at an early stage and the potential spread to
other regions when designing novel therapeutics.
The finding that pathology load in a given region is
associated with cognitive decline prompts the question
whether there is a pathological ‘threshold’ that is needed to
be breached to elicit symptoms of cognitive impairment. A
clinico-pathological study by Haroutunian and colleagues
reported no difference in HP-T load in subjects with
‘questionable dementia’ (CDR 0.5) and control subjects
(CDR 0) (Haroutunian et al. 1999). However, the study
utilized a semi-quantitative scoring system, which may not
have been sensitive enough to detect subtle differences in
pathology. Future studies using a high throughput quanti-
tative methodology, such as presented here, may reveal a
saturation point at which cognitive symptoms are clinically
observed.
Although clinico-pathological studies have been para-
mount to research into neurodegenerative dementias, data
from previous studies may be biased as they may have
assessed hallmark pathologies of one neurodegenerative
disease category only. It is apparent that neuropathological
lesions associated with neurodegenerative dementias are
not exclusive to single diseases (Jellinger 2007; Attems and
Jellinger 2013) and co-existing pathologies confer a worse
prognosis (Olichney et al. 1998; Serby et al. 2003; Kraybill
et al. 2005), therefore the presence of co-morbid patholo-
gies needs to be taken into account when conducting large
scale studies. A recent large scale clinico-pathological
correlative study by Irwin and colleagues investigated the
Fig. 5 Cases classified as having ‘severe’ pathology display a large
variation in pathology load. a Hyperphosphorylated tau (HP-T) load in
the entorhinal cortex in cases classified as neuritic Braak stage VI. b b
amyloid load in the frontal cortex in cases classified as Thal phase 5
and c a-Synuclein (a-syn) load in the cingulate cortex in Lewy body
disease (LBD) cases that are classified as McKeith neocortical LBD
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effect of concomitant pathologies in a post-mortem cohort
of cases with synucleinopathies. They report an increased
severity of Lewy body pathology in addition to AD
pathology (in particular HP-T pathology) resulted in a
shorter survival time and a shorter interval between motor
symptoms to the onset of dementia (Irwin et al. 2017).
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They also suggest that future cohorts are stratified by their
level of AD pathology in clinical trials for promising
therapeutics targeting HP-T, b amyloid and a-syn. Our
TMA methodology provides the appropriate platform to
address the issues of co-morbid pathologies in neurode-
generative diseases, as it allows serial sections to be stained
for multiple pathological lesions in a considerably shorter
time frame than traditional quantification techniques using
whole tissue sections. The construction of the TMA block
and subsequent sectioning and staining can be completed in
a day, whilst the quantification of each individually stained
TMA slides can be completed in an hour, making TMA a
reliable high throughput system. Assessment of neu-
ropathological lesions can be reliably conducted by neu-
ropathologists with a wealth of experience, such as
Professor Kurt Jellinger (Paulus et al. 1992; Bancher et al.
1997). However, quantification techniques such as the one
described in this study will allow researchers with con-
siderably less experience to assess pathology loads in
neurodegenerative diseases under the supervision of an
experienced neuropathologist or researcher with an exper-
tise in the human neuropathology of neurodegeneration.
The purpose of this quantitative TMA technique is not to
replace, but to complement diagnostic procedures, and add
value to human post-mortem tissue donated to brain banks
for research purposes. Data generated by this technique can
be incorporated into multivariate models used for clinico-
pathological studies.
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